On January 4th, Danish pharmaceutical company Novo Nordisk announced a separate research collaboration with two American biotech companies, Omega Therapeutics and Cellerity, on new therapies for cardiovascular metabolic diseases.
It is reported that Novo Nordisk is collaborating with Omega to develop an epigenome controller using the company's platform technology, aimed at enhancing metabolism as part of a potential new approach to obesity management. The collaboration between this Danish pharmaceutical company and Cellerity will build upon previous work and utilize the company's platform to develop a small molecule therapy for the treatment of metabolic dysfunction related fatty hepatitis (MASH).
Novo Nordisk stated that these are the first two projects signed under the framework cooperation between Flagship Pioneering and Novo Nordisk. Flagship Pioneering is a biotechnology company dedicated to investing in platforms and creating companies that can change the world. (Huo Xingyu)